CNQ · BETR.CN
BetterLife Pharma Inc.
CA$0.25+CA$0.01 (+4.17%)
BetterLife Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 45.65% below the high.
Loading market information…
OTC · THER · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Theralink Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Theralink Technologies, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Theralink Technologies, Inc., headquartered in Golden, Colorado, is a commercial-stage enterprise specializing in precision medicine and the generation of crucial molecular data. The company is dedicated to advancing and bringing to market innovative cancer immunotherapy products. Utilizing its proprietary platform, which focuses on phosphoprotein and protein biomarkers, alongside its sophisticated laboratory-developed test (LDT) technology, Theralink addresses diverse aspects of oncology and pharmaceutical research. Through their specialized Theralink Reverse Phase Protein Array assays, they provide highly accurate oncology data. This information enables the biopharmaceutical industry and clinical oncologists to more precisely predict which patients will respond to, or be resistant to, both FDA-approved and investigational drug treatments. Ultimately, Theralink's diagnostic assays deliver vital, actionable insights that benefit physicians, patients, and biopharmaceutical companies operating within the field of cancer care. The company adopted its current name, Theralink Technologies, Inc., in September 2020, having previously operated as OncBioMune Pharmaceuticals, Inc.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:17 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$0.25+CA$0.01 (+4.17%)
BetterLife Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 45.65% below the high.
$0.01+$0.00 (+6.67%)
ProText Mobility, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.86% below the high.
$0.10$0.00 (0.0%)
Quantum Genomics S.A.: Healthcare · Biotechnology.
$0.83+$0.06 (+8.02%)
Curative Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.32% below the high.
CA$0.04CA$0.00 (0.0%)
Glow Lifetech Corp.’s quoted price sits in the lower half of its reported 52-week range, 38.46% below the high.
$0.10$0.00 (0.0%)
Chimeric Therapeutics Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.09$0.00 (0.0%)
BioVaxys Technology Corp.’s quoted price sits in the lower half of its reported 52-week range, 56.73% below the high.
$0.02+$0.00 (+1.36%)
Bioxytran, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.42% below the high.
